1Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science, 1987, 235 (4785) : 177-182.
2Slamon D J, Leyland Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001,344 ( 11 ) : 783 -792.
3Vogel CL, Cobieigh MA, Trpathy D, et al. Efficacy and safety of Herceptin (trastuzumab, humanized anti-HER2 anti-body) as a single agent in first line treatment of HER2 overexpressing metastatic breast cancer (HER2 +/MBC ). Breast Cancer Res Treat, 1998, 50(1) :23A.
4Marry M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol,2005,23 (19) :4265-4274.
5Papaldo P, Fabi A, Ferretti G, et al. A phase Ⅱ study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol, 2006,17 (4) :630-636.
6O'Shaughnessy JA, Vukelja S, Marsland T, et al. Phase Ⅱ study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer,2004,5 (2) :142-147.
7Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase Ⅲ study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer, J Clin Oncol, 2006,24 (18) : 2786-2792.
8Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med,2005,353(16) :1673-1684.
9Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med,2006,354(8) :809-820.
